INTRODUCTION
============

Neonates have a higher risk of nosocomial infections due to humoral, cellular and myeloid cell functions combined with the use of invasive techniques (e.g., central venous catheter and endotracheal intubation) ([@b1-cln_67p831]). Because neonatal bacterial sepsis has mortality rates of 10-20% and causes morbidity in 25-30% of survivors ([@b2-cln_67p831],[@b3-cln_67p831]), effective and tolerated anti-microbiologic treatment regimens are required. Coagulase-negative *Staphylococci* and *Staphylococcus aureus* are common nosocomial bacterial pathogens, and vancomycin is the first-choice antibiotic to treat these pathogens, especially in methicillin-resistance settings ([@b4-cln_67p831]). Vancomycin is active against gram-positive bacteria. *Staphylococcus epidermis*, including methicillin-resistant strains, are inhibited by vancomycin concentrations of 1-4 µg/ml. *Staphylococcus pyogenes*, *Streptococcus pneumonia,* and *Streptococcus viridans* are susceptible to 2 µg/ml vancomycin. *Bacillus spp.* are inhibited by 2 µg/ml, *Corynebacterium spp*. by 0.04-3.1 µg/ml and *Clostridium spp*. by 0.39-6 µg/ml vancomycin ([@b5-cln_67p831]). Peak and trough concentrations of vancomycin should be \<40 μg/ml and \<10 μg/ml, respectively, to both be effective and avoid oto- or nephrotoxicity in adults ([@b6-cln_67p831],[@b7-cln_67p831],[@b8-cln_67p831]). Because vancomycin activity is primarily time-dependent, the 24-h area under the curve (AUC~0-24h~) divided by the minimum inhibitor concentration (MIC) value (AUC~0-24h~/MIC) is a better predictor of efficacy. In adults with MIC values less than 1 μg/ml, trough concentrations greater than 10 µg/ml result in AUC~0-24h~/MIC values \>400.

In subsequent analyses addressing clinical pharmacology, it is important to note that vancomycin is water-soluble, has a limited plasma protein binding capacity (i.e., IgA and albumin) and is mainly eliminated renally by glomerular filtration, although its elimination is further modulated by renal tubular transport ([@b4-cln_67p831]). Compared with adults, neonates have a higher extracellular fluid volume and a limited renal elimination capacity ([@b4-cln_67p831],[@b9-cln_67p831]). Consequently, vancomycin pharmacokinetics are different in neonates and undergo significant alterations as neonates mature. We aimed to provide a summary of published observations on vancomycin pharmacokinetics in neonates and a subsequent discussion on areas of further research.

BIBLIOGRAPHIC SEARCH
====================

The bibliographic search was performed electronically using PubMed and Embase. Searches were performed with the following keywords: \"pharmacokinetics vancomycin neonate"; "continuous infusion vancomycin neonate"; "ECMO vancomycin neonate"; "indomethacin vancomycin neonate"; "ibuprofen vancomycin neonate"; "vancomycin penetration CSF neonate" and "vancomycin toxicity neonate" with the limit of "human". All studies published in August 2011 or earlier were included in the analysis. The bibliography of each article was examined, and selected articles were read carefully. In addition, the book *Neofax: a Manual of Drugs Used in the Neonatal Care*, by Young and Mangum ([@b8-cln_67p831]), was consulted. The bibliographic search resulted in 60 original articles, 10 review articles, and two book chapters; the publication year range was from 1961 to 2011.

RESULTS
=======

Seventy-two studies were considered in this review. [Table 1](#t1-cln_67p831){ref-type="table"} summarizes vancomycin dose guidelines based on serum creatinine levels [@b10-cln_67p831]. [Table 2](#t2-cln_67p831){ref-type="table"} provides two neonatal vancomycin-dosing strategies that are based on either postmenstrual age or serum creatinine levels ([@b11-cln_67p831]). [Table 3](#t3-cln_67p831){ref-type="table"} provides dosage guidelines based on postmenstrual age and weight ([@b12-cln_67p831]). Finally, [Table 4](#t4-cln_67p831){ref-type="table"} summarizes demographic and pharmacokinetic parameters of vancomycin in neonates as reported in the literature ([@b12-cln_67p831]-[@b27-cln_67p831]).

Median estimates of vancomycin pharmacokinetics in neonates
-----------------------------------------------------------

Compared with pharmacokinetic estimates in adults, the median distribution volume is higher in neonates, and the highest estimates are in the most preterm neonates ([Table 4](#t4-cln_67p831){ref-type="table"}). In contrast, vancomycin clearance is significantly lower in neonates compared with adults after correcting for body surface area ([@b27-cln_67p831]). When expressed in ml/min/kg, the clearance estimates are lowest in the most preterm neonates (0.98 ml/min/kg) ([@b15-cln_67p831]). In addition, [Table 4](#t4-cln_67p831){ref-type="table"} illustrates that there is at least a 2- to 3-fold difference in vancomycin clearance within the neonatal age range, which in part reflects maturation and other renal functions that are related to co-morbidity characteristics in neonates ([@b12-cln_67p831]-[@b27-cln_67p831]).

Covariates that reflect maturation: creatinine, age and/or weight
-----------------------------------------------------------------

Vancomycin is almost exclusively cleared by renal glomerular filtration because renal tubular functions are still immature in neonates ([@b4-cln_67p831],[@b9-cln_67p831]). Either postmenstrual age or weight is a covariate of vancomycin clearance, presumably because these covariates serve as indicators of glomerular filtration rate maturation ([@b28-cln_67p831]). Vancomycin clearance is positively affected by weight, gestational age, postnatal age and postmenstrual age and negatively affected by creatinine levels ([@b10-cln_67p831]-[@b28-cln_67p831]). However, these covariates are interrelated because postmenstrual age is the sum of gestational and postnatal ages, whereas the correlation between weight and age is self-evident. Finally, a progressive decline in creatinine levels is associated with an increase in age ([Tables 1](#t1-cln_67p831){ref-type="table"}-[4](#t4-cln_67p831){ref-type="table"}).

Covariates reflect comorbidity characteristics
----------------------------------------------

The level of creatinine does not only reflect maturational changes, but it may also in part reflect renal impairment. At present, the use of neonatal creatinine levels to predict renal function is controversial due to residual maternal creatinine and bio-analytical issues (see the discussion section). Other comorbidity characteristics that affect vancomycin clearance are related to renal impairment, which are either primarily caused by a drug-related reduction in renal clearance or a lower endogenous renal clearance capacity or secondarily caused by a disease-related decrease in renal function ([Table 4](#t4-cln_67p831){ref-type="table"}).

As documented by Frattarelli et al., growth restriction affects vancomycin clearance capacity ([@b17-cln_67p831]) in neonates (\<28 days old), but this reduction in vancomycin clearance is limited (16-20%) and related to the reduced renal elimination capacity of these neonates ([@b19-cln_67p831],[@b29-cln_67p831]).

The association between patent ductus arteriosus (PDA) and reduced vancomycin clearance is likely related to pharmacological treatment with either ibuprofen or indomethacin. Either indomethacin or ibuprofen is administered to induce PDA closure. Asbury et al. (26, [Table 4](#t4-cln_67p831){ref-type="table"}) quantified the impact of indomethacin on vancomycin clearance. Basically, indomethacin administration for PDA closure reduced vancomycin clearance by 50% ([@b26-cln_67p831]). Allegaert ([@b30-cln_67p831]) aimed to quantify the impact of indomethacin or ibuprofen on neonatal vancomycin clearance. Allegaert et al. confirmed the effect of indomethacin on vancomycin clearance (-40%), whereas ibuprofen reduced clearance by 28%. Therefore, indomethacin has a much higher effect on vancomycin clearance compared with ibuprofen ([@b30-cln_67p831],[@b31-cln_67p831]).

Seay et al. ([@b21-cln_67p831]) reported on the population pharmacokinetics of vancomycin in 192 patients and documented that dopamine reduced vancomycin clearance ([Table 4](#t4-cln_67p831){ref-type="table"}). In contrast, when dopamine was evaluated as one of the covariates of vancomycin clearance in a data set of 214 preterm neonates, size, renal function and PMA, but neither dopamine nor respiratory support, were major contributors to clearance variability in premature neonates, which caused 18% of the variability to be unexplained ([@b28-cln_67p831]). Extra-corporeal membrane oxygenation (ECMO) provides cardiopulmonary support for patients with potentially reversible respiratory and cardiac failure. Vancomycin clearance is decreased and its distribution volume is increased in neonates on ECMO ([Table 4](#t4-cln_67p831){ref-type="table"}) ([@b24-cln_67p831],[@b25-cln_67p831]). Finally, an interaction at the level of competitive binding or inhibition of renal tubular transport processes likely explains the increase in vancomycin clearance during amoxicillin-clavulanic acid co-administration in a cohort of 70 neonates ([@b22-cln_67p831]).

Cerebrospinal fluid (CSF) pharmacokinetics of vancomycin
--------------------------------------------------------

Little is known concerning the penetration of vancomycin in neonatal CSF. Reiter and Doron ([@b32-cln_67p831]) reported CSF concentrations in three vancomycin-treated neonates. The case 1 subject was a 1264-g male who was delivered at 28 weeks of gestation, the case 2 subject was a 670-g male who was delivered at 31 weeks of gestation, and the case 3 subject was a 1150-g female who was delivered at 26 weeks of gestation. These three case subjects were treated with vancomycin at a daily dose of 20 mg/kg for 14 days. The article by Reiter and Doron ([@b32-cln_67p831]) includes additional clinical details. In case 1, the vancomycin CSF concentration was 5.6 µg/ml at 17.25 h after infusion on day 8 of therapy, and the CSF penetration rate, which was measured by the CSF to serum vancomycin concentration ratio, was 32%. In case 2, the vancomycin CSF concentration was 2.2 µg/ml at 10.7 h after intravenous administration on day 2 of the vancomycin therapy, and the CSF penetration rate of vancomycin was 26%. Patient 3 had a vancomycin CSF concentration of 5.5 µg/ml at 23 h after infusion on day 9 of the vancomycin therapy, and the CSF penetration rate was 42%. Schaad et al. ([@b27-cln_67p831]) ([Table 4](#t4-cln_67p831){ref-type="table"}) administered 10-15 mg of vancomycin intravenously to three neonates whose gestational age and body weight were unreported. The vancomycin CSF concentration range was 1.2-4.8 µg/ml (mean = 3.1 µg/ml), and the CSF penetration rate of vancomycin ranged from 7-21% (mean = 14%). Finally, Pau et al. ([@b33-cln_67p831]) reported the cases of two newborns who had received vancomycin intravenously and intra-ventricularly. The case 1 subject was a 1,280-g male who was born at 29 weeks of gestation and suffered from several diseases. This patient received the following vancomycin treatments: 50 mg/kg/day intravenously and 5-10 mg intra-ventricularly. The duration of vancomycin therapy was 26 days, and the vancomycin CSF concentration range was 12.7-92.1 µg/ml. Patient 2 was a female who was born at 31 weeks of gestation with multiple congenital anomalies. This neonate received the following vancomycin treatments: 60 mg/kg/day intravenously and 4 mg/day intraventricularly for 30 days. The vancomycin CSF concentration range was 9.5-55.3 µg/ml.

DISCUSSION
==========

Neonatal morbidity and mortality due to late-onset sepsis caused by coagulase-negative *staphylococci* or methicillin-resistant *staphylococci* has resulted in an increased necessity for the effective and safe administration of vancomycin in neonates. In the 1950s, *Staphylococcus* strains developed resistance to treatment with penicillin. Vancomycin arose as the treatment of choice for staphylococcal infections ([@b34-cln_67p831]), and its use declined in the 1960s when methicillin was preferred because of its safer toxicity profile compared with vancomycin ([@b35-cln_67p831]). In 1978, the use of vancomycin resurfaced as *Streptococcus* species developed further resistance to cephalosporins and other penicillins ([@b35-cln_67p831]).

At present, vancomycin is the current treatment of choice for many neonatal staphylococcal infections. There are, however, no reports yet on the association between indices (i.e., peak, trough, and AUC~0-24h~) of vancomycin exposure and either bactericidal effects or nephro- or ototoxicity in neonates. Consequently, the target AUC~0-24h~/MIC index (≥400) of vancomycin, which is documented in adults, is used ([@b36-cln_67p831]-[@b39-cln_67p831]). Therefore, similar to a trough concentration of 10 µg/ml of vancomycin, the AUC~0-24h~/MIC target should be considered for any dosage recommendation to minimize treatment failure in neonates. Lustar and Metsvaht ([@b38-cln_67p831]) suggested that for mid-moderate neonatal infections, the AUC~0-24h~/MIC ratio should be ≥400, and for severe infections in immunocompromised hosts, such as cases of ventilator-associated pneumonia sustained by *Staphylococcus aureus*, this ratio should be ≥850. *Staphylococcus warneri* ([@b40-cln_67p831]), which has reduced glycopeptide susceptibility (MIC\>2 µg/ml), also requires a higher vancomycin exposure.

Obviously, this target necessitates the integration of the most relevant vancomycin pharmacokinetic covariates in neonatal dosing strategies. Van den Anker ([@b39-cln_67p831]) stated that the most important dosing strategies in neonates are based on a combination of postmenstrual and postnatal ages, which considers the known changes in body composition and renal function with a higher dose for the treatment of neonatal meningitis. Such strategies have been suggested or evaluated by different groups.

Dosing guideline performance
----------------------------

Young and Mangum ([@b8-cln_67p831]) suggested a vancomycin dosage of 15 mg/kg every 12 h in meningitis patients and 10 mg/kg every 12 h for the treatment of bacteremia. When the postmenstrual age is ≤29 weeks, the vancomycin dose should be administered every 12 or 18 h according to the postnatal age (\>14 days postnatal age or younger). When the postmenstrual age range is 30-44 weeks, vancomycin should be administered every 8 or 12 h according to the postnatal age. When the postmenstrual age is ≥45 weeks, vancomycin should be administered every 6 h. This dosing guideline aims for a trough concentration between 5-10 µg/ml. However, Badran et al. ([@b41-cln_67p831]) recently illustrated that 51% of the patients in their neonatal unit attained the desired therapeutic trough concentration, and the trough concentration was \<5 µg/ml in 33% of the neonates when these guidelines were utilized.

To further illustrate the difficulties of effective dosing guideline implementation, we refer to the work of de Hoog et al. ([@b20-cln_67p831]). This group aimed to determine the best therapeutic dose for the treatment of vancomycin-sensitive bacterial infections in 108 neonates. The median gestational and postnatal ages were 28.9 weeks and 14 days, respectively, and the median body weight was 1,045 g ([Table 4](#t4-cln_67p831){ref-type="table"}). The vancomycin dose was 15 mg/kg every 12 h. Clearance was 0.057±0.0018 l/h/kg (variability = 31%); the distribution volume was 0.43±0.013 l/kg (variability = 25%), and t~½~ was 6±0.27 h (variability = 34%). Using this dosage (i.e., 15 mg/kg every 12 h), 95.5% of the initial trough concentration measurements were in the desired therapeutic range. Vancomycin trough concentrations before the second dose were 8.2±2.2 µg/ml. Trough concentrations before the fifth dose were 12.3±4.1 µg/ml. Only one trough concentration measurement was below 5 µg/ml. The vancomycin trough concentration range before the fifth dose was 15.3-20.6 µg/ml. Vancomycin accumulates in serum; accordingly, after the fifth dose, the peak concentration range was 16.6-34.5 µg/ml (mean = 25.8±5.0 µg/ml). The vancomycin trough concentration range was 5-15 µg/ml, and peak concentrations were \<40 µg/ml ([@b39-cln_67p831]) ([Table 4](#t4-cln_67p831){ref-type="table"}). The authors suggested that a vancomycin dosage of 3×10 mg/kg per day leads to a minimized high peak serum concentration and a trough serum concentration that is too low. However, this assertion was derived from a prospective validation study of 22 neonates in the same unit. However, these results are concomitant with the internal (same unit) prospective validation efforts of Seay et al. (n = 20) and Marques-Minana et al. (n = 41) ([@b21-cln_67p831],[@b22-cln_67p831]).

Intermittent vs. continuous vancomycin administration
-----------------------------------------------------

Because the AUC concept aims to maintain the vancomycin concentration above a given threshold, it has been suggested that vancomycin can be administered as a continuous infusion ([@b42-cln_67p831]-[@b45-cln_67p831]). Plan et al. ([@b42-cln_67p831]) administered vancomycin as a continuous infusion of 15-25 mg/kg/day or 20-30 mg/kg/day to 145 neonates. The body weight range of the neonates was 500-1,160 g, and their gestational age range was 26-29 weeks. Using the abovementioned dosage, bactericidal efficacy was maintained, and most subjects had serum vancomycin concentrations within the therapeutic range. Pawlotsky et al. ([@b43-cln_67p831]) administered vancomycin as a 24-h constant infusion to two neonatal groups. Group 1 (n = 24) had a postmenstrual age range of 27-41 weeks and received 10-30 mg/kg/day according to the postmenstrual age. Group 2 (n = 29) had a postmenstrual age range of 28-51.5 weeks and received a loading dose of 7 mg/kg, followed by a continuous infusion of 10-40 mg/kg/day according to the postmenstrual age. The mean vancomycin serum concentrations at steady state were 11.0±3.1 and 15.4±6.2 µg/ml in Groups 1 and 2, respectively. Both regimens were well tolerated. Oudin et al. ([@b44-cln_67p831]) confirmed the feasibility of this approach (i.e., a 7-mg/kg loading dose and constant infusion of 30 mg/kg/day) but suggested increasing the initial loading dose to 20 mg/kg, which resulted in an exposure similar to that observed by Pawlotsky et al. ([@b43-cln_67p831]).

The use and limitations of therapeutic drug monitoring
------------------------------------------------------

All pharmacokinetic studies demonstrate variability, which is only in part explained by weight, age, or creatinine level. This variability explains the use of therapeutic drug monitoring (TDM) of trough concentrations to ensure effectiveness and avoid nephrotoxicity. In contrast, the quantification of peak concentrations provides no additional monitoring value ([@b4-cln_67p831],[@b8-cln_67p831],[@b39-cln_67p831]). Vancomycin-induced nephrotoxicity and ototoxicity were previously more common than is currently observed. After eliminating impurities from the early preparations of vancomycin, the incidence of primary adverse effects, such as nephrotoxicity, ototoxicity and "red man syndrome", was reduced ([@b46-cln_67p831]). The most important risk factors for developing nephrotoxicity are the following: trough concentrations \>10 µg/ml, concomitant treatment with aminoglycosides and/or prolonged therapy (\>21 days) ([@b47-cln_67p831],[@b48-cln_67p831]). Other risk factors include high peak concentrations, high total dose, preexisting renal failure, and concurrent treatment with amphotericin and/or furosemide. However, the role of these factors in the neonatal population is not well-established ([@b49-cln_67p831]). Proper vancomycin TDM minimized both glomerular and tubular nephrotoxicity in two studies in children and neonates ([@b8-cln_67p831],[@b39-cln_67p831],[@b50-cln_67p831],[@b51-cln_67p831]). In most cases, nephrotoxicity is reversible, even after high doses ([@b52-cln_67p831]). In contrast, there is no proven association between TDM and ototoxicity prevention ([@b39-cln_67p831]).

Improving neonatal vancomycin effectiveness and tolerance
---------------------------------------------------------

Despite the number of reported pharmacokinetic studies on vancomycin in neonates, there are still relevant issues that require further consideration. First, covariates differ between the different studies, and the prospective validation of dosing guidelines is limited but urgently required to improve the predictability and extrapolation of dosing guidelines. This may be partially related to analytical issues specific to quantifying vancomycin or creatinine concentrations. Immunoassays that are routinely used to quantify vancomycin may overestimate vancomycin concentrations because of the cross-reactivity with some of the vancomycin degradation products or endogenous compounds, such as bilirubin ([@b53-cln_67p831]). The introduction of a more precise analytical method, such as liquid chromatography-tandem mass spectroscopy, should be considered. Creatinine levels initially increase and are most pronounced in the most immature neonates ([@b54-cln_67p831]). Postnatal observations also depend on techniques used to quantify creatinine levels (i.e., Jaffe colorimetry, compensated Jaffe quantification or enzymatic quantification). It is generally accepted that the Jaffe quantification method overestimates creatinine concentrations because of bilirubin and cephalosporin interference. This observation also indicates that the age- or weight-dependent creatinemia reference values will differ based on the quantification method used ([@b55-cln_67p831]). Until recently, none of the studies in the literature explicitly discussed creatinine quantification methods.

Second, the external prospective validation of vancomycin dosing guidelines is only a first step to improving the efficacy and safety/tolerance of vancomycin. The AUC~0-24h~/MIC ratio is derived from extrapolated data in adults and necessitates prospective validation in neonates that includes an analysis of the potential add-on value of continuous administration with or without a loading dose ([@b39-cln_67p831]). Finally, data in specific settings, such as ECMO or meningitis, are limited and warrant a focused approach ([@b56-cln_67p831]). Until these data emerge, there are no well-validated dosing guidelines that can be used routinely throughout the world. Therefore, we strongly recommend that neonatal units prospectively validate one of the dosing guidelines provided ([Tables 1](#t1-cln_67p831){ref-type="table"}-[4](#t4-cln_67p831){ref-type="table"}). Local validation efforts also enable caregivers to consider the local MIC values of the isolated pathogens.

In conclusion, neonatal vancomycin pharmacokinetic data were reviewed, which was followed by a critical analysis of the literature. Renal function drives vancomycin pharmacokinetics. Consequently, age or weight are the most relevant covariates of vancomycin clearance and should be considered first in neonatal vancomycin dosing guidelines and further adjusted by indicators of renal dysfunction (e.g., ECMO and ibuprofen/indomethacin). In addition to the prospective validation of vancomycin dosing guidelines that includes an analysis of its effectiveness and tolerance, studies should focus on the relevance and the methods applied for therapeutic drug monitoring and on the value of continuous vancomycin administration in neonates, whereas specific settings (i.e., ECMO and ibuprofen/indomethacin) warrant focused studies.
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###### 

Vancomycin dosage guidelines developed by Grimsley and Thomson [@b10-cln_67p831].

  Serum creatinine concentration (μmol/l)   Vancomycin (mg/kg)   Interval (h)
  ----------------------------------------- -------------------- ----------------------------
  20-29                                     20                   8
  30-39                                     20                   12
  40-49                                     15                   12
  50-59                                     12                   12
  60-79                                     15                   18
  80-100                                    15                   24
  \>100                                     15                   Check trough level at 24 h

###### 

Two neonatal vancomycin dosing strategies (postnatal age \<60 days) developed by Capparelli et al. [@b11-cln_67p831].

  Postmenstrual age (PMA)   Serum creatinine concentration (Scr)                       
  ------------------------- -------------------------------------- ---- --------- ---- ----
  ≤29                       20                                     24   ≥1.7      15   48
  30-33                     20                                     18   1.3-1.6   10   24
  34-37                     20                                     12   1.0-1.2   15   24
  38-44                     15                                     8    0.7-0.9   20   24
  ≥45                       10                                     6    ≤0.6      15   12

###### 

Initial vancomycin dosage guidelines in neonates based on postmenstrual age (PMA) or weight, developed by McDougal et al. [@b12-cln_67p831].

  PMA (weeks)   Weight (g)   Dose (mg/kg)   Interval (h)
  ------------- ------------ -------------- --------------
  \<27          \<800        18             36
  27-30         800-1200     16             24
  31-36         1200-2000    18             18
  ≥37           \>2000       15             12

###### 

Neonatal demographic data and pharmacokinetic parameters of vancomycin therapy. The results are presented as the mean±standard deviation unless otherwise stated.

  Comments                GAweeks                                        PNAdays                                         Weightg                                          n            Dosemg/kg     Clml/min/kg                                      Vdl/kg                                           t~½~ h                                           Peakµg/ml                                         Troughµg/ml                                      Reference
  ----------------------- ---------------------------------------------- ----------------------------------------------- ------------------------------------------------ ------------ ------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- ------------------------------------------------ --------------
  First dose              28.4SD 2.6                                     20.5SD 10.4                                     1069SD 435                                       15           12.6q24 h     1.22SD 0.7                                       0.53SD 0.13                                      6.0SD 2.0                                        31.2SD 12                                         9.5SD 3.5                                        ***13***
  Steady state            *The values refer to the 26-case population*   +11                                             12.6q24 h                                        1.16SD 0.6   0.52SD 0.10   6.6SD 2.1                                        46.4SD 15                                        19.4SD 9.2                                                                                                                                          
  Group 1                 26.6SD 1.7                                     18SD 8                                          908SD 254                                        16           16q24 h       1.1SD 0.07                                       0.55SD 0.02                                      6.6SD 0.35                                       28.1SD 1.2                                        3.0SD 0.6                                        ***12***
  Group 2                 29.4SD 2.0                                     23SD 14                                         1194SD 412                                       15           18q18 h       1.19SD 0.08                                      0.56SD 0.02                                      5.6SD 0.36                                       27.9SD 1.2                                        3.9SD 0.6                                        
  Group 3                 35.9SD 3.7                                     24SD 18                                         2405SD 956                                       13           15q12 h       1.36SD 0.85                                      0.57SD 0.02                                      4.9SD 0.4                                        26.1SD 1.3                                        5.5SD 0.7                                        
  Preterm                 25.9SD 1.3                                     21[a](#tfn2-cln_67p831){ref-type="table-fn"}    769SD 151                                        12           14.2SD 3.2    0.8^b^                                           0.63SD 0.025                                     10 h^b^                                          32.6SD 9.3                                        5.7SD 4.5                                        ***14***
  Group 1                 29.5SD 1.1                                     15.3SD 5.9                                      1232SD 263                                       13           *Note A*      0.98[a](#tfn2-cln_67p831){ref-type="table-fn"}   0.85[a](#tfn2-cln_67p831){ref-type="table-fn"}   11.3[a](#tfn2-cln_67p831){ref-type="table-fn"}   23.6[a](#tfn2-cln_67p831){ref-type="table-fn"}    10.5[a](#tfn2-cln_67p831){ref-type="table-fn"}   ***15**16***
  Group 2                 30.1SD 1.9                                     26.0SD 14.2                                     1289SD 265                                       12           *Note A*      0.89[a](#tfn2-cln_67p831){ref-type="table-fn"}   0.56[a](#tfn2-cln_67p831){ref-type="table-fn"}   8.7[a](#tfn2-cln_67p831){ref-type="table-fn"}    2 0.6[a](#tfn2-cln_67p831){ref-type="table-fn"}   9.9[a](#tfn2-cln_67p831){ref-type="table-fn"}    
  Preterm                 26.5SD 2.6                                     71[a](#tfn2-cln_67p831){ref-type="table-fn"}    880SD 340                                        20           *Note B*      1.2^b^                                           0.68SD 0.15                                      6.66^b^                                          n.a.                                              n.a.                                             
  SGA                     27.3SD 2.5                                     48SD 38                                         1140SD 590                                       20           n.a.          1.17[a](#tfn2-cln_67p831){ref-type="table-fn"}   0.52SD 0.26                                      7.7SD 4.9                                        31.5SD 8.3                                        6.8SD 4.2                                        ***17***
  AGA                     26.5SD 1.9                                     38SD 47                                         1535SD 986                                       123          n.a.          1.84[a](#tfn2-cln_67p831){ref-type="table-fn"}   0.72SD 0.45                                      8.0SD 6.4                                        30.6SD 10.7                                       8.3SD 6.4                                        
  GA 29 wks               29.3SD 3.4                                     29SD 20                                         1297SD 640                                       15           *Note C*      1.07SD 0.34                                      0.48SD 0.09                                      5.6SD 1.6                                        22.6SD 3.6                                        7.6SD 2.0                                        ***18***
  Populationkinetics      30SD 2.4                                       \>90%\< 2 wks                                   1000SD 840                                       116          10            2.6[a](#tfn2-cln_67p831){ref-type="table-fn"}    0.52[a](#tfn2-cln_67p831){ref-type="table-fn"}   8.5[a](#tfn2-cln_67p831){ref-type="table-fn"}    n.a.                                              n.a.                                             ***19***
  Populationkinetics      28.9^c^                                        14^c^                                           1045^c^                                          108          15q12 h       3.4SD 0.11                                       0.43SD .013                                      6.0SD0.27                                        34.3SD 7.7                                        8.2SD 2.2                                        ***20***
  Populationkinetics      29.5SD 5.1                                     16.5SD 19.6                                     14921053                                         192          *Note G*      3.5[a](#tfn2-cln_67p831){ref-type="table-fn"}    0.76[a](#tfn2-cln_67p831){ref-type="table-fn"}   13.4-33.7(range)                                 n.a.                                              n.a.                                             ***21***
  Populationkinetics      32.2SD 5.0                                     16.9SD 10.9                                     1700SD 800                                       70           15q8-24       3.96[a](#tfn2-cln_67p831){ref-type="table-fn"}   0.57[a](#tfn2-cln_67p831){ref-type="table-fn"}   6.3[a](#tfn2-cln_67p831){ref-type="table-fn"}    7.5[a](#tfn2-cln_67p831){ref-type="table-fn"}     \<20                                             ***22***
  Preterm and full-term   31.0SD 7.3                                     9.1SD 4.9                                       1620SD 550                                       11           *Note F*      0.74SD 0.20                                      0.51SD 0.03                                      7.2SD 2.9                                        28.0SD 5.4                                        4.9SD 2.0                                        ***23***
  ECMO                    38.8SD 2.2                                     12.7SD 5.1                                      3100SD 600                                       15           10q8 h        0.65SD 0.28                                      0.45SD 0.18                                      8.3SD 2.2                                        27SD 4.3                                          13.7SD 2.7                                       ***24***
  Controls                39.7SD 1.3                                     7.7SD 2.3                                       3400SD 400                                       15           10q8 h        0.79SD 0.41                                      0.39SD 0.12                                      6.5SD 2.1                                        23.0SD 5.4                                        13.2SD 4.5                                       
  ECMO                    39SD 1.4                                       1.6SD 1.7                                       3300SD 430                                       12           15-20         0.78SD 0.19                                      1.1SD 0.5                                        16.9SD 9.5                                       30[a](#tfn2-cln_67p831){ref-type="table-fn"}      5- 10                                            ***25***
  Controls                29.3SD 4.2                                     33.9SD 19.9                                     1780SD 1080                                      19           *Note D*      1.22SD 0.54                                      0.52SD 0.08                                      5.6SD 1.2                                        27.8SD 0.7                                        7.5SD 1.2                                        ***26***
  PDA(indo)               26.0SD 1.2                                     17.6SD 7.1                                      810SD 160                                        4            *Note E*      0.61SD 0.17                                      0.57SD 0.06                                      11.9SD 3.3                                       27.9SD 0.4                                        8.5SD 0.7                                        
  Preterm                 32[a](#tfn2-cln_67p831){ref-type="table-fn"}   3.3[a](#tfn2-cln_67p831){ref-type="table-fn"}   1530[a](#tfn2-cln_67p831){ref-type="table-fn"}   7            10q24 h       15ml/min/1.73 m^2^                               0.74[a](#tfn2-cln_67p831){ref-type="table-fn"}   9.8[a](#tfn2-cln_67p831){ref-type="table-fn"}    16.8[a](#tfn2-cln_67p831){ref-type="table-fn"}    5.7[a](#tfn2-cln_67p831){ref-type="table-fn"}    ***27***
  Preterm                 34[a](#tfn2-cln_67p831){ref-type="table-fn"}   4.7[a](#tfn2-cln_67p831){ref-type="table-fn"}   1570[a](#tfn2-cln_67p831){ref-type="table-fn"}   7            15q24 h       27ml/min/1.73 m^2^                               0.71[a](#tfn2-cln_67p831){ref-type="table-fn"}   5.9[a](#tfn2-cln_67p831){ref-type="table-fn"}    25.2[a](#tfn2-cln_67p831){ref-type="table-fn"}    n.a.                                             
  Term                    40[a](#tfn2-cln_67p831){ref-type="table-fn"}   2.6[a](#tfn2-cln_67p831){ref-type="table-fn"}   3070[a](#tfn2-cln_67p831){ref-type="table-fn"}   7            15q24 h       30ml/min/1.73 m^2^                               0.69[a](#tfn2-cln_67p831){ref-type="table-fn"}   6.7[a](#tfn2-cln_67p831){ref-type="table-fn"}    29.8[a](#tfn2-cln_67p831){ref-type="table-fn"}    n.a.                                             

GA = gestational age; PNA = postnatal age; n = number of cases; SGA = small for gestational age; AGA = appropriate for gestational age; ECMO = extracorporeal membrane oxygenation; PDA = patent ductus arteriosus; n.a. = not available.

Mean, SD is not available;^b^Extracted figure; ^c^Median.

Note A: The vancomycin doses were 10, 15, or 20 mg/kg.

Note B: The vancomycin dose range was 9.2-18 mg/kg.

Note C: The loading dose was 15±0.2 mg/kg, and the maintenance dose was 14.8±4.3 mg/kg.

Note D: The loading dose was 15±0.2 mg/kg, and the maintenance dose was 29.6±13.1 mg/kg.

Note E: The loading dose was 15 mg/kg, and the maintenance dose was 14.8±4. mg/kg.

Note F: The dose range was 12.1-13.8 mg/kg (12.6±0.9 mg/kg), and the dosing interval range was 13-40 h (22.0±7.5 h).

Note G: The dosing was initiated at 7.5, 10, 12, or 15 mg/kg, and the interval range was from q8 h to q24 h.

[^1]: Pacifici GM performed the systematic review and is the principal and corresponding author of the paper. Allegaert K is the second reviewer and verified the results. Both authors wrote the paper and approved the final version.
